Introduction
Tricuspid regurgitation (TR) occurs in 65 -85% of the population.
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Thus, mild TR in the setting of a structurally normal tricuspid valve (TV) apparatus can be considered a normal variant. Moderate or severe TR is usually associated with leaflet abnormalities and/or annular dilation and is usually pathologic. Primary (or organic) TR is caused by congenital or acquired abnormalities of the TV itself. Secondary (or functional) TR occurs due to deformation of the TV apparatus secondary to right-sided pressure and/or volume overload and is far more common that primary TR. It has traditionally been taught that TR should be managed medically, and that functional TR improves with treatment of the underlying cause, 3 However, recent evidence shows that prolonged right ventricular (RV) volume overload due to chronic TR may result in irreversible RV myocardial damage. 4, 5 Thus, there is a trend toward increasing volumes of TV surgery performed annually. 6 This paper reviews the anatomy, pathophysiology, diagnosis, and current management of TR.
Anatomy
The TV orifice is the largest of the four heart valves and is semilunar in shape (Figure 1 ). It consists of three leaflets (anterior, septal, and posterior) that insert into a true fibrous annulus and are separated by three commissures: anteroseptal, posteroseptal, and anteroposterior. The leaflets are connected by chordae tendinae to three papillary muscles (although multiple papillary muscles may be present). In contrast to the mitral valve, each leaflet of the TV is only connected to a single papillary muscle. The size of the leaflets varies with the anterior being largest and the septal smallest. The annulus is dynamic and changes shape throughout the cardiac cycle. Its diameter is typically 30 -35 mm, and is related to body size. Thus, the average indexed diameter is 21 mm/m 2 . As the septal portion of the annulus is fixed, dilatation of the annulus occurs primarily at the free wall. For this reason, annular sizing for TV repair is based on the size of the base of the septal leaflet. 7 The annulus is nonplanar and oval, and annuloplasty rings are appropriately shaped to cope with TV-specific anatomy. The conduction system is close to the tricuspid annulus leading to a high rate of post-operative pacemaker implantation (11.6%). 6 The rate is significantly higher after replacement compared with repair (17.2 vs. 9.5%; P ¼ 0.0001).
Incidence and pathophysiology of organic (primary) tricuspid regurgitation
Approximately 8-10% of all TR is primary. The aetiology of primary TR includes congenital abnormalities, trauma, radiation therapy, drugs, pacemaker and defibrillator leads, infective endocarditis, rheumatic fever, and myxomatous degeneration. 8 Flail leaflet is uncommon in myxomatous degeneration, but can occur with chest trauma or after endomyocardial biopsy or pacemaker implantation. The mechanisms leading to TR are different for each disease. Examples of resulting structural damage are leaflet perforation or restriction, commissural fusion, and chordal tethering. Primary TR results in pure volume overload of the right heart and therefore is usually associated with annular dilation.
Incidence and pathophysiology of functional (secondary) tricuspid regurgitation
The large majority of TR is secondary to conditions that cause RV and/or right atrial dilatation, including left-sided heart disease and chronic atrial fibrillation. During initial RV dilatation, the TV annulus dilates only at its free wall, but this process rarely results in severe TR. With further RV expansion the annulus begins to dilate in the septallateral direction, becoming increasingly planar and distorted. 9, 10 Although pulmonary hypertension is known to be associated with TR, 46% of patients with severe pulmonary hypertension have only mild TR. 11 Wall motion abnormalities of the septum can lead to leaflet tethering and TR without pulmonary hypertension. 12, 13 As in mitral valve disease, TR promotes further worsening of TR.
Natural history
The natural history of TR is not well established, in part because isolated primary TR is far less common than secondary TR and has multiple aetiologies. Topilsky et al. 14 showed that severe isolated TR is associated with a worse prognosis than the general population. In secondary TR, the underlying cause plays an important role in determining prognosis. Nevertheless, pathologic secondary TR is an independent predictor of mortality in patients with left heart failure undergoing cardiac resynchronization. 15 
Diagnosis
In mild-to-moderate isolated TR, symptoms are rarely present. In cases of advanced right heart failure, ascites, oedema, and hepatomegaly can occur. However, severe TR may present without symptoms or murmur, so TR is often diagnosed by chance during echocardiography. The holosystolic murmur typical of TR, when present, should prompt echocardiographic assessment. 16, 17 Topilsky et al. 18 showed that the respiratory variation of the murmur (Rivero-Carvallo's sign) occurs because inspiration increases annular and leads to valvular tenting. As a result, the regurgitant volume more than doubles on average during inspiration. This leads to two clinical implications: (i) as TR varies over the respiratory cycle, multiple measurements during inspiration and expiration should be performed, and (ii) clinical optimization of loading conditions may significantly decrease TR severity.
Echocardiography and grading
Currently, echocardiography is the gold standard for evaluating the mechanism and severity of TR. Transthoracic echocardiography (TTE) is used for the initial diagnosis 17, 19 ; transoesophageal echocardiography may be required in some cases, such as poor-quality TTE, endocarditis, or pacemaker lead infection. The use of 3D echocardiography allows visualization of all leaflets simultaneously.
10 Table 1 lists the criteria for grading TR according to the 2012 European Society of Cardiology (ESC) 16 and the European Association for Cardiothoracic Surgery (EACTS) Guidelines. 19 The mechanism of TR, degree of annular dilatation, and the presence of tethering should also be evaluated by echocardiography ( Figure 2 ). Significant tricuspid annular dilatation is defined by a diameter ≥40 mm or .21 mm/m 2 measured at end-diastole in the apical four-chamber transthoracic view. 18 Significant tethering is characterized as a coaptation distance .8 mm. Abnormal RV function is characterized by tricuspid annular plane systolic excursion ,1.5 cm or fractional area shortening ,35%.
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When RV function cannot be assessed reliably by echocardiography, Cardiac Magnetic Resonance Imaging is preferred because of its excellent ability to quantitate RV volumes and ejection fraction.
Treatment Conservative therapy
Conservative treatment options are very limited. In secondary TR, the underlying aetiology should be addressed. Diuretics decrease volume overload and might beneficial for patients with severe TR ).
and signs of right heart failure. 16 In patients with pulmonary hypertension, pulmonary vasodilators may lead to a reduction in TR severity. 16 
Optimal timing of surgery
Approximately 20 -30% of patients undergoing cardiac surgery for left-sided valvular disease (most often MR) present with significant TR. 21, 22 Although mortality after TV surgery has been reported to be poor, it is improving over time ( Figure 3) . 6, 23 Both European and US guidelines agree that severe TR should be treated in patients undergoing left-sided cardiac surgery. 16, 17 For moderate TR, annular dilatation (≥4 cm) and prior RV failure favour concurrent TR treatment. This is supported by a recent study demonstrating that concomitant tricuspid annuloplasty in patients with moderate TR at the time of mitral valve repair is safe and improves long-term RV remodeling. 24 Other studies have shown that concurrent TR repair reduces heart failure symptoms. 25, 26 The importance of early referral for isolated TV surgery was demonstrated by Topilsky et al. 27 who showed improved outcomes in patients with New York Heart Association (NYHA) class II symptoms compared to NYHA III and IV. When patients with severe TR are operated before they develop severe symptoms (NYHA IV), early mortality decreases to 6%. 27 Despite these data, there is no recommendation for isolated TV surgery for FTR in the European or US guidelines. 
Repair or replacement
In patients with primary TR, the extent of valve damage determines whether the valve can be repaired. For complex lesions, specific surgical repair techniques may be required and replacement may be superior to repair. Physicians and surgeons, however, need to keep in mind that no perfect prosthetic valve to replace the TV is available.
When TR is due to pacemaker implantation, repositioning of the lead may improve TR when the lead itself interferes with leaflet closure. On the other hand, perforation of a leaflet by a pacemaker lead may require surgical repair. In functional TR, there is a clear trend favouring repair, now performed in up to 89% of TV surgeries in the USA. 23 Marquis-Gravel et al. 28 however, demonstrated a rate of persistent severe TR (grade 3/4) after TV repair of 13% compared with 2% after replacement. Nevertheless, TV repair is preferred over replacement when a high likelihood of post-operative patent valve function can be expected. Thus a detailed pre-and intra-operative evaluation of valve pathology is essential for decision-making regarding whether repair or replacement is favourable in individual cases.
Tricuspid valve repair
The main goal of TR repair is the restoration of leaflet coaptation. Because annular dilation is usually present in severe TR, ring annuloplasty should be performed in all patients. Kilic et al. 23 showed that in the majority of cases (75.5%) isolated annuloplasty is the technique used to restore TV competence. The DeVega annuloplasty, originally described in 1972, was for decades the standard technique for TV repair. 29 It was largely abandoned after several studies showed a lower rate of recurrent TR after the implantation of annuloplasty rings. 30, 31 Whether flexible or rigid rings should be used is controversial. In a retrospective analysis of 2277 patients undergoing TV surgery, Navia et al. 30 and colleagues found a lower rate of recurrent TR with a rigid annuloplasty ring compared with a flexible ring or De Vega annuloplasty. On the other hand, Pfannmueller and colleagues reported a higher rate of annuloplasty dehiscence after the implantation of a rigid ring. 32 Although annuloplasty is sufficient to correct TR in most cases of functional TR due to annular dilatation, high rates of residual TR despite annuloplasty are reported when leaflet tethering is the primary mechanism. 33 Pre-operative coaptation height predicts the severity of residual TR, with a 55% chance of residual TR with a coaptation height .1.0 cm. 34 Tenting volume ≥2.3 mL (sensitivity of 100%, specificity of 84%) measured by 3D echocardiography also predicts severe residual TR. 33 Anterior leaflet augmentation has been reported to reduce the rate of residual TR by extending the coaptation length and locating the coaptation point deep into the RV. ).
Chronic atrial fibrillation often accompanies TR and is a risk factor for late severe TR after left-sided valve surgery. 36, 37 Intra-operative ablation can reduce the risk of TR progression. 38, 39 However, ablation is only successful in 60 -82% of patients at 12-month followup. 38 -41 The success rate depends on the type of atrial fibrillation (chronic vs. paroxysmal) and the size of the left atrium.
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Tricuspid valve replacement
Both mechanical and bioprosthetic valves are available for TV replacement. From 2000 until 2010, the rate of bioprosthesis usage in the USA increased from 77.4 to 86.6%. 23 Replacement is indicated over annuloplasty in patients with primary TR with significant valvular pathology. However, it is debatable whether mechanical valves or biological valves are preferred. Some argue that a mechanical prosthesis should be used in younger patients with a long life expectancy. 42 The advantage of a bioprosthesis is that it does not require long-term anticoagulation. A bioprotheses may be preferred for additional reasons: (i) life expectancy may be limited; (ii) due to a lower flow rate and decreased pressure in the tricuspid position, there is an increased risk for valve thrombosis despite adequate anticoagulation (reported to be up to 20%) or valve dysfunction due to pannus after mechanical valve replacement.
-45
Percutaneous tricuspid valve therapy
At present, there are few options for percutaneous therapy. Offlabel usage of TAVR devices for valve-in-valve procedures in biological TV prostheses has been reported. 46 Implantation of TAVR devices in the inferior and superior vena cava with case reports showing feasibility with an immediate abolition of retrograde flow into the inferior vena cava. 47, 48 The first successful transcatheter tricuspid repair for severe TR was recently reported using the Mitralign system (Mitralign Inc., Tewksbury, MA, USA), 49 to perform a plication of the TV annulus. As this is only a single case report, efficacy and durability remain unknown. There have also been unpublished reports of using the MitraClip device for secondary TR. With the development of transcatheter prostheses in the mitral position, several of which currently being in clinical trials, we can expect some of those systems to be eventually implanted on the right side of the heart as well.
Conclusions
Primary TR is caused by pathological abnormalities of the TV apparatus. Severe primary TR is associated with adverse prognosis and should prompt consideration for surgical management. Secondary TR is far more common and occurs due to annular dilation, pulmonary hypertension, and/or leaflet tethering in the setting of right-or left-sided heart disease. Treatment of the underlying heart disease should be performed and may improve TR. In patients undergoing cardiac surgery for left-sided heart disease, moderate or severe TR should be treated. 
